Dario Baratti
达里奥·巴拉蒂
MD
Senior Surgical Oncologist, Peritoneal Tumors Program腹膜肿瘤项目高级外科肿瘤学家
👥Biography 个人简介
Dario Baratti is a senior member of the Peritoneal Tumours Program at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, collaborating closely with Marcello Deraco. His research focuses on long-term outcome analysis of CRS + HIPEC across multiple peritoneal malignancies, quality of life after surgery, and intraoperative pharmacological optimization of HIPEC drug delivery.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Long-term Survival Analysis After CRS + HIPEC
Published extensive single-institution long-term follow-up data on CRS + HIPEC outcomes for peritoneal mesothelioma, colorectal peritoneal metastases, and appendiceal tumors, providing 10- and 15-year survival benchmarks used for patient counseling.
Quality of Life After Cytoreductive Surgery
Investigated health-related quality of life trajectories following CRS + HIPEC, demonstrating recovery to baseline functional status within 3–6 months in the majority of patients and supporting the procedure's acceptability to patients and multidisciplinary teams.
HIPEC Pharmacokinetics and Drug Dosing Optimization
Conducted pharmacokinetic studies of intraperitoneal cisplatin and doxorubicin during HIPEC, contributing to evidence-based dosing protocols that maximize tumor tissue exposure while minimizing systemic toxicity.
Representative Works 代表性著作
Long-term follow-up and prognostic analysis of cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma
Annals of Surgical Oncology (2013)
15-year outcomes analysis from Milan demonstrating durable long-term survival in peritoneal mesothelioma following complete CRS + HIPEC, with epithelioid subtype achieving 10-year survival.
Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies
European Journal of Surgical Oncology (2016)
Prospective QoL study showing meaningful recovery of functional status and patient-reported outcomes after CRS + HIPEC, supporting the procedure in appropriately selected patients.
Intraoperative pharmacokinetics of cisplatin during hyperthermic intraperitoneal chemotherapy: impact of temperature and perfusion time
Surgical Oncology (2011)
Pharmacokinetic analysis demonstrating temperature-dependent enhancement of cisplatin tumor penetration, providing mechanistic rationale for hyperthermia in HIPEC protocols.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 达里奥·巴拉蒂 的研究动态
Follow Dario Baratti's research updates
留下邮箱，当我们发布与 Dario Baratti（Fondazione IRCCS Istituto Nazionale dei Tumori, Milan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment